RESEARCH ARTICLE. Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke
|
|
- Phillip Andrews
- 6 years ago
- Views:
Transcription
1 RESEARCH ARTICLE Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke Maarten G. Lansberg, MD, PhD, 1 Soren Christensen, PhD, 1 Stephanie Kemp, 1 Michael Mlynash, MD, MS, 1 Nishant Mishra, MD, PhD, 1 Christian Federau, MD, 1 Jenny P. Tsai, MD, 1 Sun Kim, MD, 1 Raul G. Nogueria, MD, 2 Tudor Jovin, MD, 3 Thomas G. Devlin, MD, 4 Naveed Akhtar, MD, 5 Dileep R. Yavagal, MD, 6 Diogo Haussen, MD, 2 Seena Dehkharghani, MD, 7 Roland Bammer, PhD, 8 Matus Straka, PhD, 9 Greg Zaharchuk, MD, 8 Michael P. Marks, MD, 8 and Gregory W. Albers, MD 1 for the CT Perfusion to Predict Response to Recanalization in Ischemic Stroke Project (CRISP) Investigators Objective: To assess the utility of computed tomographic (CT) perfusion for selection of patients for endovascular therapy up to 18 hours after symptom onset. Methods: We conducted a multicenter cohort study of consecutive acute stroke patients scheduled to undergo endovascular therapy within 90 minutes after a baseline CT perfusion. Patients were classified as target mismatch if they had a small ischemic core and a large penumbra on their baseline CT perfusion. Reperfusion was defined as >50% reduction in critical hypoperfusion between the baseline CT perfusion and the 36-hour follow-up magnetic resonance imaging. Results: Of the 201 patients enrolled, 190 patients with an adequate baseline CT perfusion study who underwent angiography were included (mean age 5 66 years, median NIH Stroke Scale [NIHSS] 5 16, median time from symptom onset to endovascular therapy hours). Rate of reperfusion was 89%. In patients with target mismatch (n 5 131), reperfusion was associated with higher odds of favorable clinical response, defined as an improvement of 8 points on the NIHSS (83% vs 44%; p , adjusted odds ratio [OR] 5 6.6, 95% confidence interval [CI] ). This association did not differ between patients treated within 6 hours (OR 5 6.4, 95% CI ) and those treated > 6 hours after symptom onset (OR , 95% CI ). Interpretation: The robust association between endovascular reperfusion and good outcome among patients with the CT perfusion target mismatch profile treated up to 18 hours after symptom onset supports a randomized trial of endovascular therapy in this patient population. ANN NEUROL 2017;00: Recent randomized controlled trials have demonstrated benefit from endovascular therapy for patients with acute ischemic stroke who were treated predominantly in the <6-hour time window. 1 5 Based on these studies, current guidelines recommend endovascular therapy for patients with occlusion of the internal carotid artery or middle cerebral artery who can be treated within 6 hours after symptom onset. 6 Whether endovascular therapy is View this article online at wileyonlinelibrary.com. DOI: /ana Received Jan 23, 2017, and in revised form May 3, Accepted for publication May 4, Address correspondence to Dr Lansberg, Stanford Stroke Center, 780 Welch Road, Suite 350, Palo Alto, CA lansberg@stanford.edu From the 1 Department of Neurology, Stanford University, Stanford, CA; 2 Department of Neurology, Emory University, Atlanta, GA; 3 Department of Neurology, University of Pittsburgh, Pittsburgh, PA; 4 Chattanooga Center for Neurologic Research, Chattanooga, TN; 5 Department of Radiology, Saint Luke s Health System, Kansas City, MO; 6 Department of Neurology, University of Miami, Miami, FL; 7 Department of Radiology, Emory University, Atlanta, GA; 8 Department of Radiology, Stanford University, Stanford, CA; and 9 Stanford University, Stanford, CA VC 2017 American Neurological Association 1
2 ANNALS of Neurology FIGURE 1: Computed tomographic (CT) perfusion target mismatch examples. The top panel shows the CT perfusion study of a patient who has the target mismatch pattern. The ischemic core (pink lesion) is 4.2ml. The volume of critically hypoperfused tissue (green lesion) is 77.1ml. The absolute mismatch volume is 72.9ml, and the mismatch ratio is All these values meet target mismatch criteria. The bottom panel shows the CT perfusion study of a patient who does not meet target mismatch criteria. The core lesion exceeds the 70ml threshold, and the mismatch ratio does not meet the >1.8 criterion. CBF 5 cerebral blood flow. also beneficial for patients outside of the 6-hour time window is unknown. Whereas most studies have demonstrated a gradual decrease in the effectiveness of endovascular therapy with longer onset-to-treatment times, 7 9 our group has shown that good outcome rates in reperfused patients who meet magnetic resonance imaging (MRI) diffusion perfusion mismatch criteria remain relatively constant over time. 10 These findings suggest that patient selection criteria will play a key role in determining the outcome of endovascular thrombectomy trials in the extended time window. A main drawback of MRI-based patient selection is the small percentage of hospitals that have magnetic resonance (MR) readily available for the assessment of acute stroke patients. Therefore, the time it takes to obtain an MRI scan to triage acute stroke patients is unacceptably long in most hospitals. Another drawback of MRI is the relatively large percentage of patients who have contraindications to MRI because of metal implants (eg, pacemakers) or claustrophobia. To overcome the limitations of MRI-based patient selection, computed tomographic (CT) perfusion imaging can be used instead. CT is much more widely available and has fewer contraindications than MRI. It is, however, not known whether CT perfusion-based patient selection is comparable to MRI. Before embarking on a randomized trial with imagebased patient selection, we therefore conducted the CT Perfusion to Predict Response to Recanalization in Ischemic Stroke Project (CRISP) study to examine the utility of CT perfusion in identifying patients who are likely to benefit from endovascular therapy. 2 Volume 00, No. 00
3 Lansberg et al: Results of the CRISP Study Patients and Methods Study Design CRISP was a multicenter prospective cohort study of acute stroke patients who underwent a CT perfusion scan before endovascular therapy. The institutional review board at each site approved the study, and informed consent for participation was obtained from each patient or, if the patient was mentally incompetent to consent, their proxy. Study Patients and Protocol Patients were enrolled at 6 U.S. hospitals between 2012 and Patients were eligible for participation in the study if they: (1) were at least 18 years old, (2) had an ischemic stroke with an NIH Stroke Scale (NIHSS) score of 5 or more, (3) were scheduled to undergo endovascular therapy for the stroke, and (4) had undergone a CT perfusion and CT angiogram within 90 minutes prior to scheduled endovascular therapy. Patients who had a pre-existing illness resulting in a modified Rankin Scale (mrs) score of 2 or higher prior to the qualifying stroke were excluded. CT perfusion imaging was performed using the institutions routine protocols. CT perfusion studies were postprocessed using RAPID (ischemaview, Menlo Park, CA) to generate maps of the ischemic core (regional cerebral blood flow < 30%) and critically hypoperfused tissue (time to the maximum of the residue function [Tmax] > 6 seconds). RAPID automatically segmented and calculated volumes of the ischemic core and of the critically hypoperfused tissue. These maps were available for viewing by local investigators, who determined patients target mismatch status based on the RAPID CT perfusion maps. Target mismatch was defined as an ischemic core < 70ml, a difference between critically hypoperfused tissue and ischemic core volumes > 15ml, a ratio between critically hypoperfused tissue and ischemic core volumes > 1.8, and a Tmax > 10 seconds lesion < 100ml (Fig 1). Although physicians could use the results of the noncontrast CT, the CT angiogram, and their routine CT perfusion maps to guide treatment decisions, they were instructed not to use the RAPID maps to make treatment decisions. Consequently, patients underwent endovascular therapy regardless of their target mismatch status. The device and method used for endovascular therapy was based on operator preference and included treatment with stent retrievers, manual aspiration, intra-arterial thrombolytic agents, and/or angioplasty with or without stenting. Patients underwent an early follow-up MRI, obtained within 36 hours after the baseline CT perfusion scan. Patients who could not undergo a follow-up MRI because of a contraindication underwent a follow-up CT scan instead. Patients returned for clinical follow-up on days 30 and 90. During these visits, trained investigators rated patients on the NIHSS, the mrs, the Glasgow Outcome Scale, and the Barthel Index. If patients were unable to return to clinic, study coordinators made every attempt to visit the patients at their residence. If this was not possible, assessments were made by phone. FIGURE 2: Flow diagram of study participants. Of the 201 patients enrolled, 190 were included in the analyses of patients with baseline computed tomographic perfusion (CTP) who underwent endovascular treatment. Of these, 131 had the target mismatch profile on CTP, whereas 59 did not. Clinical and Radiological Endpoints The primary clinical endpoint was favorable neurological response, defined as an 8-point or more improvement on the NIHSS between baseline and day 30 or an NIHSS score of 1 at day 30. This endpoint was chosen because it is sensitive to the effects of early reperfusion and to match the primary endpoint of the DEFUSE 1 and 2 studies. The secondary clinical endpoint was functional independence, defined as mrs 2 on day 90. Symptomatic intracranial hemorrhage (sich), defined as any intracranial hemorrhage associated with a 4-point worsening on the NIHSS, was used as a safety endpoint. Core Imaging Laboratory Stanford s core imaging laboratory assessed (1) the Alberta Stroke Program Early CT score on the baseline noncontrast CT scan; (2) the ischemic core and critical hypoperfused tissue volumes on the baseline CT perfusion maps, if needed after removal of imaging artifacts; (3) the location of the primary arterial occlusive lesion and the Thrombolysis in Cerebral Infarction (TICI) reperfusion score on the digital subtraction angiography images; and (4) the volume of persistent critical hypoperfused tissue (Tmax > 6 seconds) and presence of hemorrhagic transformation on the follow-up MRI. Reperfusion was defined as >50% reduction in critically hypoperfused tissue (Tmax > 6 seconds lesion volume) between baseline CT perfusion and the follow-up MRI, or TICI 2b/3 at completion of endovascular therapy if a follow-up MRI was not performed or technically inadequate. Statistical Analysis Percentages of favorable neurological response were compared between groups using Fisher exact tests. The effect of reperfusion on binary outcomes was assessed using logistic regression with and without adjustment for imbalances in baseline Month
4 ANNALS of Neurology TABLE 1. Baseline Characteristics in Patients Included in the CTP Profile Cohort Characteristic Target Mismatch, n No Target Mismatch, n 5 59 Mean (SD) age, yr 66 (15) 66 (15) Female sex, No. [%] a 75 [57] 15 [25] Hypertension, No. [%] 86 [66] 42 [71] Diabetes mellitus, No. [%] b 22 [17] 20 [34] Hyperlipidemia, No. [%] 48 [37] 28 [48] Atrial fibrillation, No. [%] 43 [33] 17 [29] Prior stroke/tia, No. [%] 12 [9] 9 [15] Median NIHSS score {IQR} 15 {11 19} 20 {16 23} Intravenous tpa pretreatment, No. [%] 58 [44] 30 [51] Median {IQR} time from symptom onset to start of CTP, hr Median {IQR} time from symptom onset to femoral puncture, hr Median {IQR} time from arrival at study site to endovascular therapy, hr 4.6 { } 3.5 { } 5.6 { } 4.6 { } 1.3 { } 1.0 { } Median {IQR} volume of infarct core, ml 4 {0 13} 23 {3 44} Median {IQR} volume of perfusion lesion, ml 104 {69 144} 194 { } Vessel occlusion on angiogram, No. [%] Internal carotid artery, proximal 13 [10] 9 [15] Internal carotid artery, distal 22 [17] 10 [17] Middle cerebral artery, proximal 73 [56] 34 [58] Middle cerebral artery, distal 20 [15] 6 [10] Other 2 [2] 0 [0] None 0 [0] 0 [0] a p < 0.001, b p CTP 5 computed tomographic perfusion; IQR 5 interquartile range; CTP 5 CT perfusion; NIHSS 5 NIH Stroke Scale; SD 5 standard deviation; TIA 5 transient ischemic attack; tpa 5 tissue plasminogen activator. variables. Baseline variables were entered into the multivariate model if they were significant at a p < 0.1 level in univariate analysis, and were retained in the multivariate model if they were significant at a p < The effect of reperfusion on the overall distribution of outcomes on the mrs (shift analysis) was assessed with the assumption-free ordinal analysis that uses the Wilcoxon Mann Whitney generalized odds ratio (OR). 11,12 Analyses were conducted using SPSS and SAS software. Results Of the 201 patients enrolled, 190 patients with anterior circulation strokes and a good quality baseline CT perfusion who underwent digital subtraction angiography were included in the primary analyses. Eleven patients were excluded; 2 withdrew from the study, 2 did not undergo catheter angiography, 6 had inadequate baseline CT perfusion, and 1 had an occlusion in the posterior circulation (Fig 2). The mean age of the patient population was years, median NIHSS was 16 (interquartile range [IQR] ), and median time from symptom onset to endovascular therapy was 5.2 hours (IQR ). Femoral puncture occurred > 6 hours after symptom onset in 40% (n 5 75). The majority of these patients fell into the 6- to 9-hour window (61%), with fewer patients 4 Volume 00, No. 00
5 Lansberg et al: Results of the CRISP Study FIGURE 3: Functional outcome in patients with target mismatch stratified by reperfusion and time to treatment. Numbers in bars indicate the percentage of patients in each category of the modified Rankin Scale. Among patients with the target mismatch (n 5 131), reperfusion was associated with an increased rate of functional independence on day 90. The adjusted odds ratio for independence with reperfusion was 11.2 (95% confidence interval [CI] ) in patients treated within 6 hours (n 5 71) compared to 18.2 (95% CI ) in patients treated beyond 6 hours (n 5 60). in the 9- to 12-hour (17%) and the > 12-hour time window (21%). In 84% of the late (>6 hour) treated patients, the exact time of onset was not known (ie, wake-up strokes) and the time of onset was therefore based on the time the patient was last known to be well. One hundred thirty-one patients had the target mismatch profile. The baseline characteristics for patients with and without the target mismatch profile are listed in Table 1. The percentage of patients with target mismatch was 62% in the < 6-hour window, 83% in the 6- to 9-hour window, 85% in the 9- to 12-hour window, and 69% in the > 12-hour window. Overall, the percentage of patients with target mismatch was lower in the <6-hour window than in the >6-hour window (62% vs 80%; p ). Rate of reperfusion, determined primarily on the 36-hour perfusion scan, was 90% (87% TICI 2b/3). The rate of reperfusion did not differ between patients with femoral puncture <6 hours versus > 6 hours (90% vs 89%; p 5 1.0) nor between patients with and without target mismatch (87% vs 95%; p ). Among patients with the target mismatch (n 5 131), reperfusion was associated with increased odds of favorable clinical response (83% vs 44%; p , OR 5 6.1, 95% confidence interval [CI] ). This association remained significant when adjusted for age and NIHSS (OR 5 6.6, 95% CI ). The results were similar with independence (mrs 5 0 2) as the outcome; patients with the target mismatch (n 5 131) had increased odds of independence with reperfusion in unadjusted analysis (66% vs 29%; p , OR 5 4.6, 95% CI ) and after adjustment for NIHSS and age (OR , 95% CI ). The shift analysis also showed improved functional outcome with reperfusion (generalized OR 5 2.7, 95% CI ). Rates of functional independence were similar in target mismatch patients with reperfusion who were treated <6 hours versus > 6 hours (70% vs 62%; p unadjusted and p adjusted), suggesting that time does not modify the effect of reperfusion among patients with target mismatch. Also, in multivariate analysis, the effect of reperfusion on functional independence among patients with the target mismatch was not modified by time to treatment (p for the interaction between reperfusion and time to treatment when time is dichotomized at 6 hours; p when time is modeled as a continuous variable). The adjusted OR for independence with reperfusion was 11.2 (95% CI ) in patients treated within 6 hours (n 5 71) compared to 18.2 (95% CI ) in patients treated beyond 6 hours (n 5 60; Fig 3). When favorable clinical response was the endpoint instead of functional independence, results were similar, with an adjusted OR of 6.4 (95% CI ) in patients treated within 6 hours compared to 13.7 (95% CI ) in patients treated beyond 6 hours (p for difference between ORs). The effect of reperfusion could not be assessed in patients without the target mismatch because of the Month
6 ANNALS of Neurology TABLE 2. No Target Mismatch Lesion Patterns No Target Mismatch Lesion Pattern Imaging Criteria (ischemic core, Tmax lesion volume) Total, No. Reperfusion, No. mrs 0 2 among Reperfused, % Large Tmax10 lesion isch. core < 70ml, Tmax10 > 100ml Large ischemic core isch. core > 70ml, Tmax10 < 100ml 1 0 Large ischemic core and Tmax10 lesion isch. core > 70ml, Tmax10 < 100ml Small ischemic core and Tmax6 lesion isch. core < 15 ml, Tmax6 < 15ml Matched ischemic core and Tmax6 lesion isch. core ml, ratio Tmax6/isch. core < TOTAL mrs 5 modified Rankin Scale; isch. core 5 ischemic core; Tmax 5 time to the maximum of the residue function; Tmax6 5 Tmax > 6 seconds; Tmax10 5 Tmax > 10 seconds. relatively small size (n 5 59) and the high rate of reperfusion (95%) of this subgroup. When compared to patients with target mismatch, the rate of functional independence in the setting of reperfusion was lower among patients without target mismatch in unadjusted analysis (45% vs 66%; p ), but this difference did not remain significant after adjustment (p 5 0.2); the rate of favorable clinical response was lower in unadjusted (62% vs 83%; p ) and adjusted (p ) analysis. Patients who do not meet target mismatch criteria make up a heterogeneous population with large, small, and matched lesion patterns (Table 2). The most common pattern was a Tmax > 10 seconds lesion exceeding 100ml and an ischemic core volume < 70ml (n 5 45). Fortyfour of these patients reperfused, and their rate of independence was not significantly different from target mismatch patients with reperfusion (52% vs 66%; p 5 0.1). The overall rate of sich was 5.3%. Rates of sich were similar between patients who underwent endovascular therapy following intravenous tissue plasminogen activator (tpa; n 5 88) and patients who did not receive intravenous tpa (n 5 102; 5.7% vs 4.9%; p 5 1.0), and between patients with symptom onset to groin puncture < 6 and > 6 hours (5.2% vs 5.3%; p 5 1.0). There was also no significant association between other baseline parameters (baseline NIHSS, age, ischemic core volume, critically hypoperfused tissue volume, time to treatment or reperfusion, target mismatch status, reperfusion) and sich. Discussion This study demonstrates a robust association between endovascular reperfusion and favorable clinical outcomes in patients who present with a target mismatch pattern on their baseline CT perfusion scan. It also shows that this association extends well beyond the currently established 6-hour time window for endovascular therapy for acute stroke. These results support randomized controlled trials of endovascular therapy in the extended time window for patients with a target mismatch pattern on CT perfusion. The findings of this study are consistent with prior studies that evaluated the response to reperfusion in patients selected with MR perfusion imaging. Specifically, in the DEFUSE 2 study, which had the same design as CRISP but used MRI instead of CT to classify patients, reperfusion was associated with a 26% (57% vs 31%) absolute increase in functional independence among patients with an MRI-based target mismatch profile. This is similar to the 37% (66% vs 29%) absolute increase in functional independence among patients with a CT-based target mismatch profile observed in this study. These findings suggest that CT perfusion is as effective as MRI at selecting patients who are likely to benefit from endovascular therapy. Our results are also consistent with the results of the EXTEND-IA study, a trial of early thrombectomy in patients selected with very similar CT perfusion imaging criteria. 3 Despite much earlier treatment in EXTEND-IA (median time hours) compared to CRISP (median time hours), the studies saw similar increases in functional independence with endovascular reperfusion (42% in EXTEND-IA and 37% in CRISP). That treatment effects were similar despite a much shorter time to treatment in EXTEND-IA suggests that time may be a less critical factor among patients who meet mismatch criteria. This suggestion is supported by our finding that 6 Volume 00, No. 00
7 Lansberg et al: Results of the CRISP Study the positive association between reperfusion and rate of functional independence was similar among target mismatch patients who were treated early (<6 hours) and those who were treated late (>6 hours), a result that is consistent with our findings in DEFUSE 2, which demonstrated that the effect of reperfusion was similar among early and late treated patients with an MRI target mismatch pattern. 10 Our finding that rates of sich were almost identical among early and late treated patients (5.2% vs 5.3%) points to the safety of endovascular treatment of patients with target mismatch in the delayed time window (>6 hours). A pooled analysis of the endovascular treatment arms of 4 recent clinical trials showed a smaller gain in functional independence with reperfusion (12%) than the CRISP, DEFUSE 2, and EXTEND-IA studies. 13 Differences in study subjects and study methodology may account for this. First, most patients included in the pooled analysis were not selected with perfusion imaging and may therefore have had less tissue at risk of infarction than patients in the CRISP, DEFUSE 2 and EXTEND-IA studies. Second, in the pooled analysis reperfusion was defined as a TICI 2b/3 score at the completion of the endovascular procedure, whereas reperfusion was assessed on early (<36 hours) follow-up perfusion scans in the other studies. Although this is unlikely to account for large differences, the effect of reperfusion in the pooled analysis may have been attenuated by patients with TICI 2b/3 reperfusion following mechanical thrombectomy who reoccluded the affected artery postprocedure. Our study has limitations. First, because CRISP was a cohort study without a control group, no definitive conclusion can be drawn about the effect of endovascular treatment. The results are, however, suggestive that there may be benefit from endovascular therapy, even in the delayed time window. Second, the very high reperfusion rate, a tribute to the efficacy of stent retrievers, was unexpected and limited our ability to compare outcomes between patients with and without reperfusion. This was particularly true among patients without a target mismatch, because virtually all patients without a target mismatch (68 of 71) reperfused. We can therefore not draw any direct conclusions about the effect of reperfusion among patients without target mismatch. The DEFUSE 2 study, which showed no association between reperfusion and good functional outcome in patients without target mismatch on MRI, suggests that there also is no (strong) association between reperfusion and good functional outcome in patients without target mismatch on CT. However, DEFUSE 2 was not powered to demonstrate an effect of reperfusion in patients without target mismatch. Moreover, results from the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) study have shown no effect modification of endovascular treatment according to CT mismatch status. 14 Also, patients without target mismatch form a heterogeneous population of large, small, and matched lesion patterns (see Table 2), and it is likely that the response to reperfusion differs between these subsets. It is therefore possible that certain patients without a CT target mismatch do benefit from reperfusion, such as the subset of patients who had an ischemic core < 70ml but who were classified as non target mismatch because of a large (>100ml) lesion with a Tmax delay > 10 seconds. Third, because the exact time of stroke onset was unknown for most patients, a subanalysis that excluded these patients was not feasible. Finally, although investigators were instructed not to use the perfusion maps generated by our automated CT perfusion analysis software for decision making regarding endovascular therapy, they could use their standard of care perfusion software for this purpose. Some patients were likely excluded from our study because they did not undergo endovascular therapy based on the results of the standard of care CT perfusion maps. Exclusion of patients on those grounds may have occurred preferentially in patients presenting late, given that the proportion of target mismatch was higher among patients who were treated beyond 6 hours and given that patients with target mismatch had longer symptom onset to imaging times. Although enrichment of our study population with target mismatch patients does not bias the main results of our study, the proportion of patients with target mismatch in the general stroke population is likely smaller than the 69% observed among all patients in this study and certainly lower than the 80% observed among patients treated after 6 hours. In summary, the CRISP results provide compelling evidence that multimodal CT with CT perfusion can be used in an extended time window to select patients who are likely to benefit from endovascular reperfusion. The favorable response to reperfusion among patients with a CT target mismatch pattern was similar to that observed in the DEFUSE 2 study among patients with an MR target mismatch pattern. Together these studies laid the foundation for the currently ongoing randomized controlled trial of endovascular therapy in patients selected with either multimodal CT or MRI (DEFUSE 3; ClinicalTrials.gov NCT ). Acknowledgment The study was funded by 2 grants from the NIH National Institute of Neurological Disorders and Stroke (principal investigators, M.G.L. and G.W.A.). Month
8 ANNALS of Neurology We thank the members of the Data and Safety Monitoring board (Drs W. Smith, University of California, San Francisco [chair]; J. English, California Pacific Medical Center; G. Howard, University of Alabama at Birmingham; and P. Sanelli, North Shore LIJ Health System). Author Contributions M.G.L., S.Ke., M.M., R.B., M.S., G.Z., M.P.M., and G.W.A. conceived and designed the study. M.G.L., S.C., S.Ke., M.M., N.M., C.F., J.P.T., S.Ki., R.G.N., T.J., T.G.D., N.A., D.R.Y., D.H., S.D., M.P.M., and G.W.A. acquired and analyzed the data. M.G.L. drafted the manuscript. The CRISP study group is further composed of D. Thai (Stanford Medical Center, Stanford, CA), K. Armbruster and S. DeCesare (University of Pittsburgh Medical Center, Pittsburgh, PA), B. Brion (St Luke s Hospital, Kansas City, MO), K. Schindler and L. Craft (Emory University, Atlanta, GA), K. Barton and T. Massengale (Chattanooga Center for Neurologic Research, Chattanooga, TN), and K. Ramdas (University of Miami, Miami, FL). Potential Conflicts of Interest S.C. receives consultant fees from ischemaview, which produces the software used in this trial for postprocessing of CT perfusion studies. T.G.D. received consulting fees and grant funding from Covidien/Medtronic, which manufactures stent retrievers used to treat patients in this study. D.R.Y. serves on the trial steering committee of Covidien/ Medtronic and received consulting fees from Covidien/ Medtronic. T.J. received a research grant from Stryker Neurovascular, consulting fees from Covidien/Medtronic, and payment for travel expenses from Stryker Neurovascular; all 3 companies manufacture stent retrievers used to treat patients in this study. M.P.M. received consulting fees from Covidien/Medtronic. R.G.N. received a research grant from Stryker Neurovascular, serves on the Trial Executive Committee for Penumbra, serves on the Trial Steering Committee for Covidien/Medtronic, and serves as the angiographic Core Lab for the STAR trial funded by Covidien/Medtronic; all 3 companies manufacture stent retrievers used to treat patients in this study. G.W.A. received consulting fees from Covidien/Medtronic. G.W.A., R.B., and M.S. received consulting fees and are shareholders of ischemaview, which produces the software used in this trial for postprocessing of CT perfusion studies, and they hold a patent related to that software. References 1. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-pa vs. t-pa alone in stroke. N Engl J Med 2015;372: Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372: Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372: Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372: Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372: Powers WJ, Derdeyn CP, Biller J, et al American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2015;46: Saver JL, Goyal M, van der Lugt A, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA 2016;316: Khatri P, Abruzzo T, Yeatts SD, et al. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology 2009;73: Khatri P, Yeatts SD, Mazighi M, et al. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol 2014;13: Lansberg MG, Cereda CW, Mlynash M, et al. Response to endovascular reperfusion is not time-dependent in patients with salvageable tissue. Neurology 2015;85: Agresti A. Generalized odds ratios for ordinal data. Biometrics 1980;36: Churilov L, Arnup S, Johns H, et al. An improved method for simple, assumption-free ordinal analysis of the modified Rankin Scale using generalized odds ratios. Int J Stroke 2014;9: Campbell BC, Hill MD, Rubiera M, et al. Safety and efficacy of solitaire stent thrombectomy: individual patient data meta-analysis of randomized trials. Stroke 2016;47: Borst J, Berkhemer OA, Roos YB, et al. Value of computed tomographic perfusion-based patient selection for intra-arterial acute ischemic stroke treatment. Stroke 2015;46: Volume 00, No. 00
Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke
Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke Maarten G. Lansberg, Stanford University Soren Christensen, Stanford University Stephanie Kemp, Stanford University
More informationUpdate on Early Acute Ischemic Stroke Interventions
Update on Early Acute Ischemic Stroke Interventions Diana Goodman MD Lead Neurohospitalist Maine Medical Center Assistant Professor of Neurology, Tufts University School of Medicine I have no disclosures
More informationBroadening the Stroke Window in Light of the DAWN Trial
Broadening the Stroke Window in Light of the DAWN Trial South Jersey Neurovascular and Stroke Symposium April 26, 2018 Rohan Chitale, MD Assistant Professor of Neurological Surgery Vanderbilt University
More informationEffect of Collateral Blood Flow on Patients Undergoing Endovascular Therapy for Acute Ischemic Stroke
Effect of Collateral Blood Flow on Patients Undergoing Endovascular Therapy for Acute Ischemic Stroke Michael P. Marks, MD; Maarten G. Lansberg, MD; Michael Mlynash, MD; Jean-Marc Olivot, MD; Matus Straka,
More informationMechanical thrombectomy beyond the 6 hours. Mahmoud Rayes, MD Medical Director, Stroke program Greenville Memorial Hospital
Mechanical thrombectomy beyond the 6 hours Mahmoud Rayes, MD Medical Director, Stroke program Greenville Memorial Hospital Disclosures None Worldwide statistics 1 IN 6 people will have a stroke at some
More informationThrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
Original Article Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging G.W. Albers, M.P. Marks, S. Kemp, S. Christensen, J.P. Tsai, S. Ortega-Gutierrez, R.A. McTaggart, M.T. Torbey,
More informationEndovascular Treatment for Acute Ischemic Stroke
ular Treatment for Acute Ischemic Stroke Vishal B. Jani MD Assistant Professor Interventional Neurology, Division of Department of Neurology. Creighton University/ CHI health Omaha NE Disclosure None 1
More informationEndovascular Treatment Updates in Stroke Care
Endovascular Treatment Updates in Stroke Care Autumn Graham, MD April 6-10, 2017 Phoenix, AZ Endovascular Treatment Updates in Stroke Care Autumn Graham, MD Associate Professor of Clinical Emergency Medicine
More informationUPDATES IN INTRACRANIAL INTERVENTION Jordan Taylor DO Metro Health Neurology 2015
UPDATES IN INTRACRANIAL INTERVENTION Jordan Taylor DO Metro Health Neurology 2015 NEW STUDIES FOR 2015 MR CLEAN ESCAPE EXTEND-IA REVASCAT SWIFT PRIME RECOGNIZED LIMITATIONS IV Alteplase proven benefit
More informationEndovascular Stroke Therapy
Endovascular Stroke Therapy Update with Emphasis on Practical Clinical and Imaging Considerations Sachin Kishore Pandey, MD, FRCPC Disclosures I have no relevant financial disclosures or conflict of interest
More informationSEE IT. BELIEVE IT. THE CONFIDENCE OF CLARITY. Solitaire Platinum. Revascularization Device
SEE IT. BELIEVE IT. THE CONFIDENCE OF CLARITY. Revascularization THE CONFIDENCE OF CLARITY. The key features that make the device effective have been retained including our unique Parametric overlapping
More informationHypoperfusion Intensity Ratio Predicts Infarct Progression and Functional Outcome in the DEFUSE 2 Cohort
Hypoperfusion Intensity Ratio Predicts Infarct Progression and Functional Outcome in the DEFUSE 2 Cohort Jean Marc Olivot, MD, PhD; Michael Mlynash, MD, MS; Manabu Inoue, MD, PhD; Michael P. Marks, MD;
More informationPatient selection for i.v. thrombolysis and thrombectomy
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 8 Acute treatment and early secondary prevention of stroke Level 2 Patient selection for
More informationStroke Treatment Beyond Traditional Time Windows. Rishi Gupta, MD, MBA
Stroke Treatment Beyond Traditional Time Windows Rishi Gupta, MD, MBA Director, Stroke and Neurocritical Care Endovascular Neurosurgery Wellstar Health System THE PAST THE PRESENT 2015 American Heart Association/American
More informationEndovascular Therapy for Acute Ischemic Stroke: Reducing Door-to-puncture Time
DOI: 10.5797/jnet.oa.2016-0140 Endovascular Therapy for Acute Ischemic Stroke: Reducing Door-to-puncture Time Yoichi Morofuji, 1,2 Nobutaka Horie, 1,2 Yohei Tateishi, 2,3 Minoru Morikawa, 4 Eisaku Sadakata,
More informationMechanical thrombectomy in Plymouth. Will Adams. Will Adams
Mechanical thrombectomy in Plymouth Will Adams Will Adams History Intra-arterial intervention 1995 (NINDS) iv tpa improved clinical outcome in patients treated within 3 hours of ictus but limited recanalisation
More informationMechanical Thrombectomy of Large Vessel Occlusions Using Stent Retriever Devices
Mechanical Thrombectomy of Large Vessel Occlusions Using Stent Retriever Devices Joey English MD, PhD Medical Director, Neurointerventional Services California Pacific Medical Center Hospitals, San Francisco,
More informationSignificant Relationships
Opening Large Vessels During Acute Ischemic Stroke Significant Relationships Wade S Smith, MD, PhD Director UCSF Neurovascular Service Professor of Neurology Daryl R Gress Endowed Chair of Neurocritical
More informationCT Perfusion is Essential for Stroke Triage. Maarten Lansberg, MD PhD Associate Professor of Neurology Stanford University, Stanford Stroke Center
CT Perfusion is Essential for Stroke Triage Maarten Lansberg, MD PhD Associate Professor of Neurology Stanford University, Stanford Stroke Center CT Perfusion is Essential for Stroke Triage Disclosures:
More informationStrokecenter Key lessons of MR CLEAN study
Strokecenter Key lessons of MR CLEAN study Diederik Dippel Disclosures Funded by the Dutch Heart Foundation Nominal, unrestricted grants from AngioCare BV Medtronic/Covidien/EV3 MEDAC Gmbh/LAMEPRO Penumbra
More informationACUTE ISCHEMIC STROKE. Current Treatment Approaches for Acute Ischemic Stroke
ACUTE ISCHEMIC STROKE Current Treatment Approaches for Acute Ischemic Stroke EARLY MANAGEMENT OF ACUTE ISCHEMIC STROKE Rapid identification of a stroke Immediate EMS transport to nearest stroke center
More informationThe DAWN of a New Era for Wake-up Stroke
The DAWN of a New Era for Wake-up Stroke Alan H. Yee, D.O. Stroke and Critical Care Neurology Department of Neurology University of California Davis Medical Center Objectives Review Epidemiology and Natural
More informationStroke Update Elaine J. Skalabrin MD Medical Director and Neurohospitalist Sacred Heart Medical Center Stroke Center
Stroke Update 2015 Elaine J. Skalabrin MD Medical Director and Neurohospitalist Sacred Heart Medical Center Stroke Center Objectives 1. Review successes in systems of care approach to acute ischemic stroke
More informationAcute Stroke Treatment: Current Trends 2010
Acute Stroke Treatment: Current Trends 2010 Helmi L. Lutsep, MD Oregon Stroke Center Oregon Health & Science University Overview Ischemic Stroke Neuroprotectant trials to watch for IV tpa longer treatment
More informationStroke Clinical Trials Update Transitioning to an Anatomic Diagnosis in Ischemic Stroke
Stroke Clinical Trials Update Transitioning to an Anatomic Diagnosis in Ischemic Stroke Alexander A. Khalessi MD MS Director of Endovascular Neurosurgery Surgical Director of NeuroCritical Care University
More informationESCAPE Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times
ESCAPE Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times Michael D Hill, Mayank Goyal on behalf of the ESCAPE Trial
More informationRBWH ICU Journal Club February 2018 Adam Simpson
RBWH ICU Journal Club February 2018 Adam Simpson 3 THROMBOLYSIS Reperfusion therapy has become the mainstay of therapy for ischaemic stroke. Thrombolysis is now well accepted within 4.5 hours. - Improved
More informationMechanical Thrombectomy: Where Are We Now? T. Adam Oliver, MD Tallahassee Neurological Clinic Tallahassee, Florida TMH Neurosymposium June 11, 2016
Mechanical Thrombectomy: Where Are We Now? T. Adam Oliver, MD Tallahassee Neurological Clinic Tallahassee, Florida TMH Neurosymposium June 11, 2016 none DISCLOSURES Where did we come from? Spiotta, et
More informationComparison of Five Major Recent Endovascular Treatment Trials
Comparison of Five Major Recent Endovascular Treatment Trials Sample size 500 # sites 70 (100 planned) 316 (500 planned) 196 (833 estimated) 206 (690 planned) 16 10 22 39 4 Treatment contrasts Baseline
More informationframework for flow Objectives Acute Stroke Treatment Collaterals in Acute Ischemic Stroke framework & basis for flow
Acute Stroke Treatment Collaterals in Acute Ischemic Stroke Objectives role of collaterals in acute ischemic stroke collateral therapeutic strategies David S Liebeskind, MD Professor of Neurology & Director
More information12/4/2017. Disclosures. Study organization. Stryker Medtronic Penumbra Viz Route 92. Data safety monitoring board Tudor G.
12/4/2017 Update on Stroke Trials:Extending the Window DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo NP001713
More informationEndovascular Treatment for Acute Ischemic Stroke: Considerations from Recent Randomized Trials
Published online: March 13, 2015 1664 9737/15/0034 0115$39.50/0 Review Endovascular Treatment for Acute Ischemic Stroke: Considerations from Recent Randomized Trials Manabu Shirakawa a Shinichi Yoshimura
More informationBest medical therapy (includes iv t-pa in eligible patients)
UDATE ON REVASCAT: (Randomized Trial Of Revascularization With Solitaire FR Device Versus Best Medical Therapy In The Treatment Of Acute Stroke Due To Anterior Circulation Large Vessel Occlusion Presenting
More informationInterventional Treatment of Stroke
Interventional Treatment of Stroke Andrew F. Ducruet, MD Barrow Neurological Institute 2018 BNI Stroke Rehab Symposium October 13, 2018 Disclosures Consultant: Medtronic, Penumbra, Cerenovus Lecture Overview
More informationPredictors of Poor Outcome after Successful Mechanical Thrombectomy in Patients with Acute Anterior Circulation Stroke
THIEME Original Article 139 Predictors of Poor Outcome after Successful Mechanical Thrombectomy in Patients with Acute Anterior Circulation Stroke Yosuke Tajima 1 Michihiro Hayasaka 1 Koichi Ebihara 1
More informationDrano vs. MR CLEAN Review of New Endovascular Therapy for Acute Ischemic Stroke Patients
Drano vs. MR CLEAN Review of New Endovascular Therapy for Acute Ischemic Stroke Patients Peter Panagos, MD, FACEP, FAHA Associate Professor Emergency Medicine and Neurology Washington University School
More informationComparison of Magnetic Resonance Imaging Mismatch Criteria to Select Patients for Endovascular Stroke Therapy
Comparison of Magnetic Resonance Imaging Mismatch Criteria to Select Patients for Endovascular Stroke Therapy Nishant K. Mishra, MBBS, PhD, FESO; Gregory W. Albers, MD; Søren Christensen, PhD; Michael
More informationParameter Optimized Treatment for Acute Ischemic Stroke
Heart & Stroke Barnett Memorial Lectureship and Visiting Professorship Parameter Optimized Treatment for Acute Ischemic Stroke December 2, 2016, Thunder Bay, Ontario Adnan I. Qureshi MD Professor of Neurology,
More informationAdvances in Neuro-Endovascular Care for Acute Stroke
Advances in Neuro-Endovascular Care for Acute Stroke Ciarán J. Powers, MD, PhD, FAANS Associate Professor Program Director Department of Neurological Surgery Surgical Director Comprehensive Stroke Center
More informationNeuro-vascular Intervention in Stroke. Will Adams Consultant Neuroradiologist Plymouth Hospitals NHS Trust
Neuro-vascular Intervention in Stroke Will Adams Consultant Neuroradiologist Plymouth Hospitals NHS Trust Stroke before the mid 1990s Swelling Stroke extension Haemorrhagic transformation Intravenous thrombolysis
More informationRelative cerebral blood volume is associated with collateral status and infarct growth in stroke patients in SWIFT PRIME
Original Article Relative cerebral blood volume is associated with collateral status and infarct growth in stroke patients in SWIFT PRIME Journal of Cerebral Blood Flow & Metabolism 0(00) 1 9! Author(s)
More informationPopulations Interventions Comparators Outcomes Individuals: With acute stroke who are being evaluated for thrombolysis.
Protocol Computed Tomography Perfusion Imaging of the Brain (60149) Medical Benefit Effective Date: 01/01/16 Next Review Date: 03/19 Preauthorization Yes Review Dates: 11/14, 11/15, 11/16, 03/17, 03/18
More informationMR RESCUE: Primary Results
MR RESCUE: Primary Results (Mechanical Retrieval and REcanalization of Stroke Clots Using Embolectomy) Funded by NIH-NINDS UCLA SPOTRIAS Grant: P50 NS044378 Clinical Trials.gov Number NCT00389467 FDA IDE
More informationFigures for Draft Response to IMS III, MR RESCUE, and SYNTHSESIS Trials
Figures for Draft Response to IMS III, MR RESCUE, and SYNTHSESIS Trials Figure 1: Lay Press Judgment May Belie a Deeper Examination of the Data. Truman ultimately defeated Dewey for the Presidency Subject
More informationMechanical endovascular thrombectomy for acute ischemic stroke: a retrospective multicenter study in Belgium
DOI 10.1007/s13760-015-0552-7 ORIGINAL ARTICLE Mechanical endovascular thrombectomy for acute ischemic stroke: a retrospective multicenter study in Belgium Niels Fockaert 1 Marieke Coninckx 2 Sam Heye
More informationMedical Policy. MP Computed Tomography Perfusion Imaging of the Brain
Medical Policy MP 6.01.49 BCBSA Ref. Policy: 6.01.49 Last Review: 09/28/2017 Effective Date: 09/28/2017 Section: Radiology Related Policies 2.01.54 Endovascular Procedures for Intracranial Arterial Disease
More informationEpidemiology. Epidemiology 6/1/2015. Cerebral Ischemia
Presenter Disclosure Information Paul Nyquist MD/MPH FCCM FAHA Updates on the Acute Care of Ischemic Stroke and Intracranial Hemorrhage Updates on the Acute Care of Ischemic Stroke Paul Nyquist MD/MPH,
More informationThe SWIFT PRIME trial (Solitaire With the Intention for
Predictive Value of RAPID Assessed Perfusion Thresholds on Final Infarct Volume in SWIFT PRIME (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment) Maxim Mokin, MD, PhD; Elad
More informationEndovascular stroke research after MRCLEAN. W. van Zwam
1 Endovascular stroke research after MRCLEAN W. van Zwam 2 Layout 1. What do we know by now 2. Next research questions Anesthesia Aspiration 3. Ongoing and future research Dutch initiatives 3 4 N=70 Intervention
More informationThrombectomy in Octogenarians in the Era of Stent Retriever: Is an Age Limit Necessary?
Journal of Neuroendovascular Therapy 2017; 11: 563 569 Online July 10, 2017 DOI: 10.5797/jnet.oa.2017-0031 Thrombectomy in Octogenarians in the Era of Stent Retriever: Is an Age Limit Necessary? Yosuke
More informationEndovascular Clot Retrieval. Teddy Wu Neurologist (and Stroke enthusiast) Christchurch Hospital
Endovascular Clot Retrieval Teddy Wu Neurologist (and Stroke enthusiast) Christchurch Hospital Something you can do tomorrow Melbourne half marathon 2016 In 2009 Simple approach to stroke - blocked artery,
More informationAHA/ASA Guideline. Downloaded from by on November 7, 2018
AHA/ASA Guideline 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular
More informationHERMES Time and Workflow Primary Paper. Statistical Analysis Plan
HERMES Time and Workflow Primary Paper Statistical Analysis Plan I. Study Aims This is a post-hoc analysis of the pooled HERMES dataset, with the following specific aims: A) To characterize the time period
More informationHistorical. Medical Policy
Medical Policy Subject: Mechanical Embolectomy for Treatment of Acute Stroke Policy #: SURG.00098 Current Effective Date: 01/01/2016 Status: Revised Last Review Date: 08/06/2015 Description/Scope This
More informationSupplementary Online Content
Supplementary Online Content Lapergue B, Blanc R, Gory B, et al; ASTER Trial Investigators. Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic
More informationCVA Updates Karen Greenberg, DO, FACOEP. Director Neurologic Emergency Department Crozer Chester Medical Center
CVA Updates 2018 Karen Greenberg, DO, FACOEP Director Neurologic Emergency Department Crozer Chester Medical Center Disclosure I have the following financial relationship with the manufacturer of any commercial
More informationPr Roman Sztajzel Service de Neurologie HUG
Pr Roman Sztajzel Service de Neurologie HUG Conflict of interest: none IV THROMBOLYSIS AND ENDOVASCULAR THROMBECTOMY approved treatments of acute stroke main criteria time (delay) IV thrombolysis radiological
More informationPARADIGM SHIFT FOR THROMBOLYSIS IN PATIENTS WITH ACUTE ISCHAEMIC STROKE, FROM EXTENSION OF THE TIME WINDOW TO RAPID RECANALISATION AFTER SYMPTOM ONSET
PARADIGM SHIFT FOR THROMBOLYSIS IN PATIENTS WITH ACUTE ISCHAEMIC STROKE, FROM EXTENSION OF THE TIME WINDOW TO RAPID RECANALISATION AFTER SYMPTOM ONSET Hye Seon Jeong, *Jei Kim Department of Neurology and
More informationSpontaneous Recanalization after Complete Occlusion of the Common Carotid Artery with Subsequent Embolic Ischemic Stroke
Original Contribution Spontaneous Recanalization after Complete Occlusion of the Common Carotid Artery with Subsequent Embolic Ischemic Stroke Abstract Introduction: Acute carotid artery occlusion carries
More information5/31/2018. Interventional Therapies that Expand Time Windows for Acute Ischemic Stroke Treatment. Disclosures. Impact of clot burden
Good Outcome (%) Rankin 0-2 at 90 days 5/31/2018 Interventional Therapies that Expand Time Windows for Acute Ischemic Stroke Treatment Disclosures Cerenovus: I am on Executive Committee for ARISE2 Trial
More informationFive recent clinical trials have
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Bijoy K. Menon, MD,
More informationImaging Stroke: Is There a Stroke Equivalent of the ECG? Albert J. Yoo, MD Director of Acute Stroke Intervention Massachusetts General Hospital
Imaging Stroke: Is There a Stroke Equivalent of the ECG? Albert J. Yoo, MD Director of Acute Stroke Intervention Massachusetts General Hospital Disclosures Penumbra, Inc. research grant (significant) for
More informationRESEARCH ARTICLE. Ischemic Core Thresholds Change with Time to Reperfusion: A Case Control Study
RESEARCH ARTICLE Ischemic Core Thresholds Change with Time to Reperfusion: A Case Control Study Andrew Bivard, PhD, 1 Tim Kleinig, PhD, FRACP, 2 Ferdinand Miteff, FRACP, 1 Kenneth Butcher, FRACP, 3 Longting
More informationTwo-Year Outcome after Endovascular Treatment for Acute Ischemic Stroke
Original Article Two-Year Outcome after Endovascular Treatment for Acute Ischemic Stroke Lucie A. van den Berg, M.D., Marcel G.W. Dijkgraaf, Ph.D., Olvert A. Berkhemer, M.D., Ph.D., Puck S.S. Fransen,
More informationDisclosure. Advances in Interventional Neurology. Disclosure. Natural History of Disease 3/15/2018. Vishal B. Jani MD
Advances in Interventional Neurology Disclosure Vishal B. Jani MD Medical Director Vascular Neurology Consultant Interventional Neurology CHI Health Assistant Professor, Creighton University School of
More informationBY MARILYN M. RYMER, MD
Lytics, Devices, and Advanced Imaging The evolving art and science of acute stroke intervention. BY MARILYN M. RYMER, MD In 1996, when the US Food and Drug Administration (FDA) approved the use of intravenous
More informationDespite recent cerebrovascular advances, ischemic
CLINICAL ARTICLE J Neurosurg 126:1123 1130, 2017 Comparison of non stent retriever and stent retriever mechanical thrombectomy devices for the endovascular treatment of acute ischemic stroke Kate A. Hentschel,
More informationInterventional Stroke Treatment
Interventional Stroke Treatment Vishal B. Jani MD Medical Director Vascular Neurology Consultant Interventional Neurology CHI Health Assistant Professor, Creighton University School of Medicine Omaha,
More informationCT/MRI 第 42 回日本脳卒中学会講演シンポジウム 総説 はじめに. MRI magnetic resonance imaging DWI diffusion-weighted. DWI/CBF malignant profile
第 42 回日本脳卒中学会講演シンポジウム 総説 CT/MRI 1 要旨 rt-pa MRI magnetic resonance imaging DWI diffusion-weighted image Tmax time-to-maximum DWI/PWI perfusion image mismatch CT computed tomography CBF cerebral blood flow
More informationBGS Spring Conference 2015
Neuroradiology in hyperacute stroke: what is the UK position? Dr Shelley Renowden Bristol NICE HIS July, 2013 The current evidence on mechanical clot retrieval for treating acute ischaemic stroke shows
More information1/19/2018. Endovascular Therapy for Stroke
Endovascular Therapy for Stroke 1 PROACT II (1999, IA urokinase)first to demonstrate benefit of EST Newer trials (including MERCI in 2005) demonstrated vessel recanalization but no clinical benefit 2 Based
More informationEndovascular Procedures (Angioplasty and/or Stenting) for Intracranial Arterial Disease (Atherosclerosis and Aneurysms)
Endovascular Procedures (Angioplasty and/or Stenting) for Intracranial Arterial Disease (Atherosclerosis and Aneurysms) Policy Number: 2.01.54 Last Review: 11/2018 Origination: 4/2006 Next Review: 11/2019
More informationACUTE STROKE IMAGING
ACUTE STROKE IMAGING Mahesh V. Jayaraman M.D. Director, Inter ventional Neuroradiology Associate Professor Depar tments of Diagnostic Imaging and Neurosurger y Alper t Medical School at Brown University
More informationThe Effect of Diagnostic Catheter Angiography on Outcomes of Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment
The Effect of Diagnostic Catheter Angiography on Outcomes of Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Adnan I. Qureshi, MD 1, Muhammad A. Saleem, MD 1, Emrah Aytaç, MD
More informationAcute Ischemic Stroke Imaging. Ronald L. Wolf, MD, PhD Associate Professor of Radiology
Acute Ischemic Stroke Imaging Ronald L. Wolf, MD, PhD Associate Professor of Radiology Title of First Slide of Substance An Illustrative Case 2 Disclosures No financial disclosures Off-label uses of some
More informationEndovascular Treatment of Ischemic Stroke
Endovascular Treatment of Ischemic Stroke William Thorell, MD Associate Professor Neurosurgery UNMC Co-Director Stroke and Neurovascular Center Nebraska Medicine Overview Definitions of terms Review basic
More informationFrom interventional cardiology to cardio-neurology. A new subspeciality
From interventional cardiology to cardio-neurology. A new subspeciality in the future? Prof. Andrejs Erglis, MD, PhD Pauls Stradins Clinical University Hospital University of Latvia Riga, LATVIA Disclosure
More informationIntra-arterial Stroke Therapy: 2018 Update
Intra-arterial Stroke Therapy: 2018 Update Expanding the Treatment Window Parita Bhuva, M.D. Medical Director Enrolling investigator Stryker Neurovascular (DAWN trial) Disclosures Most common large vessel
More informationSentinel Stroke National Audit Programme (SSNAP) Based on stroke patients admitted to hospital for thrombectomy between April 2016 and March 2017
Thrombectomy Sentinel Stroke National Audit Programme (SSNAP) Thrombectomy Report for April 2016 - March 2017 National results July 2017 Based on stroke patients admitted to hospital for between April
More informationStroke Cart Improves Efficiency in Acute Ischemic Stroke Intervention
Stroke Cart Improves Efficiency in Acute Ischemic Stroke Intervention MR Amans, F Settecase, R Darflinger, M Alexander, A Nicholson, DL Cooke, SW Hetts, CF Dowd, RT Higashida, VV Halbach Interventional
More informationABSTRACT. n engl j med 372;24 nejm.org june 11,
The new england journal of medicine established in 1812 june 11, 2015 vol. 372 no. 24 Stent-Retriever Thrombectomy after vs. t-pa Alone in Stroke Jeffrey L. Saver, M.D., Mayank Goyal, M.D., Alain Bonafe,
More informationA Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke Chelsea S. Kidwell, M.D., Reza Jahan, M.D., Jeffrey Gornbein,
More informationHow to Interpret CT/CTA for Acute Stroke in the Age of Endovascular Clot Retrieval
How to Interpret CT/CTA for Acute Stroke in the Age of Endovascular Clot Retrieval Peter Howard MD FRCPC Disclosures No conflicts to disclose How to Interpret CT/CTA for Acute Stroke in the Age of Endovascular
More informationEndovascular Treatment for Acute Ischemic Stroke: Curtis A. Given II, MD Co-Director, Neurointerventional Services Baptist Physician Lexington
Endovascular Treatment for Acute Ischemic Stroke: Curtis A. Given II, MD Co-Director, Neurointerventional Services Baptist Physician Lexington Disclosures: SWIFT PRIME site (Medtronic) Physician Proctor
More informationMechanical Endovascular Reperfusion Therapy
Get With the Guidelines Stroke Mechanical Endovascular Reperfusion Therapy February 1, 2017 Speaker Lee H. Schwamm, MD Executive Vice Chairman and Director of Stroke/TeleStroke Services, Department of
More informationISA consensus statement: Recommendations for the Early Management of Acute Ischemic Stroke with Endovascular Treatment.
ISA consensus statement: Recommendations for the Early Management of Acute Ischemic Stroke with Endovascular Treatment. 1. Endovascular Treatment of Ischemic Stroke: Early reperfusion is crucial for the
More informationAcute brain vessel thrombectomie: when? Why? How?
Acute brain vessel thrombectomie: when? Why? How? Didier Payen, MD, Ph D Université Paris 7 Département Anesthesiologie-Réanimation Univ Paris 7; Unité INSERM 1160 Hôpital Lariboisière AP-HParis current
More informationUpdates on Endovascular Therapy
Updates on Endovascular Therapy 5 th Annual Intermountain Stroke Conference October 16, 2017 M. Shazam Hussain, MD, FRCP(C), FAHA Director, Cerebrovascular Center Associate Professor, CCLCM Staff, Vascular
More informationExtra- and intracranial tandem occlusions in the anterior circulation - clinical outcome of endovascular treatment in acute major stroke.
Extra- and intracranial tandem occlusions in the anterior circulation - clinical outcome of endovascular treatment in acute major stroke. Poster No.: C-1669 Congress: ECR 2014 Type: Scientific Exhibit
More informationPopulations Interventions Comparators Outcomes Individuals: With acute stroke who are being evaluated for thrombolysis. are: are: are: are:
Protocol Computed Tomography Perfusion Imaging of the Brain (60149) Medical Benefit Effective Date: 01/01/16 Next Review Date: 03/18 Preauthorization Yes Review Dates: 11/14, 11/15, 11/16, 03/17 Preauthorization
More informationACUTE ISCHEMIC STROKE
ENDOVASCULAR MECHANICAL THROMBECTOMY IN PATIENTS WITH ACUTE ISCHEMIC STROKE HHS Stroke Annual Review March 7 and March 8, 2018 Objectives To review the stroke endovascular mechanical thrombectomy evidence
More informationCase Report Successful Mechanical Thrombectomy of a Middle Cerebral Artery Occlusion 14 Hours after Stroke Onset
Hindawi Case Reports in Neurological Medicine Volume 2017, Article ID 9289218, 4 pages https://doi.org/10.1155/2017/9289218 Case Report Successful Mechanical Thrombectomy of a Middle Cerebral Artery Occlusion
More informationBackground. Recommendations for Imaging of Acute Ischemic Stroke: A Scientific Statement From the American Heart Association
for Imaging of Acute Ischemic Stroke: A Scientific Statement From the American Heart Association An Scientific Statement from the Stroke Council, American Heart Association and American Stroke Association
More informationUvA-DARE (Digital Academic Repository) Intra arterial treatment for acute ischemic stroke Berkhemer, O.A. Link to publication
UvA-DARE (Digital Academic Repository) Intra arterial treatment for acute ischemic stroke Berkhemer, O.A. Link to publication Citation for published version (APA): Berkhemer, O. A. (2016). Intra arterial
More informationEndovascular Therapy: Beyond the Guidelines
Endovascular Therapy: Beyond the Guidelines Ashutosh P. Jadhav, MD PhD Assistant Professor, Neurology and Neurological Surgery Center for Neuro-endovascular Therapy UPMC Stroke Institute Pittsburgh, PA
More informationIschemic Core and Hypoperfusion Volumes Predict Infarct Size in SWIFT PRIME
RESEARCH ARTICLE Ischemic Core and Hypoperfusion Volumes Predict Infarct Size in SWIFT PRIME Gregory W. Albers, MD, 1 Mayank Goyal, MD, 2 Reza Jahan, MD, 3 Alain Bonafe, MD, 4 Hans-Christoph Diener, MD,
More informationOngoing Acute Stroke Studies 10/5/2015
Ongoing Acute Stroke Studies 10/5/2015 Wade S. Smith, MD, PhD Director UCSF Neurovascular Service Daryl R. Gress Professor of Neurocritical Care and Stroke Disclosures NIH U10 NS 086494 (PI) NorCal RCC
More informationSupplementary Online Content
Supplementary Online Content Badhiwala JH, Nassiri F, Alhazzani W, et al. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. JAMA. doi:10.1001/jama.2015.13767. etable 1. The modified
More information